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A B S T R A C T
The catabolic process of macroautophagy, through the rapid degradation of unwanted cellular components, is
involved in a multitude of cellular and organismal functions that are essential to maintain homeostasis. Those
functions include adaptation to starvation, cell development and diﬀerentiation, innate and adaptive immunity,
tumor suppression, autophagic cell death, and maintenance of stem cell stemness. Not surprisingly, an im-
pairment or block of macroautophagy can lead to severe pathologies. A still increasing number of reports, in
particular, have revealed that mutations in the autophagy-related (ATG) genes, encoding the key players of
macroautophagy, are either the cause or represent a risk factor for the development of several illnesses. The aim
of this review is to provide a comprehensive overview of the diseases and disorders currently known that are or
could be caused by mutations in core ATG proteins but also in the so-called autophagy receptors, which provide
speciﬁcity to the process of macroautophagy. Our compendium underlines the medical relevance of this pathway
and underscores the importance of the eventual development of therapeutic approaches aimed at modulating
macroautophagy.
1. Introduction
1.1. Autophagy, its eﬀectors and their coding genes
Cells, tissues and organisms have to respond to a multitude of en-
vironmental, developmental and metabolic cues, and this is also
achieved through the lysosomal turnover of intracellular components,
via a set of pathways grouped under the term autophagy, from the
Greek words for ‘self-eating’ (autos and phagein). Autophagic processes
deliver long-lived, dysfunctional or aggregated proteins, damaged or
superﬂuous organelles and invading pathogens to the lysosome for
turnover, and the resulting degradation products are reused for ana-
bolic processes or as a source of energy. There are three major types of
autophagy: microautophagy, chaperone-mediated autophagy and
macroautophagy [1]. During microautophagy, the lysosome directly
engulfs and degrades parts of the cytoplasm through invagination and
pinching oﬀ of its limiting membrane. Chaperone-mediated autophagy
translocates proteins carrying a speciﬁc pentapeptide from the cyto-
plasm directly into the lysosome. Macroautophagy, in contrast, involves
the sequestration of cytoplasmic components into a transient structure
termed the phagophore that matures into a double-membrane vesicle
called an autophagosome, which subsequently fuses with the lysosome
to deliver its cargo (Fig. 1). The focus of this review is on macro-
autophagy, hereafter referred to as autophagy.
Autophagy is a tightly regulated process and the key players of this
pathway are the AuTophaGy-related (ATG) proteins. Screens in yeast
have lead so far to the isolation of 41 ATG genes, and several of them
have one or more counterparts in mammalian cells, including the 16
that are part of the conserved ATG machinery that mediates the for-
mation of autophagosomes in all eukaryotes [2]. Additional tissue- and
organism-speciﬁc ATG genes have been identiﬁed in more complex
eukaryotes [3]. The ATG core proteins have been classiﬁed in ﬁve
functional groups (Table 1): I) The ULK kinase complex, composed of
ULK1 or ULK2, ATG13, RB1CC1/FIP200 and ATG101; II) the class III
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phosphatidylinositol 3-kinase (PtdIns3K) complex, composed of
BECN1/Beclin 1, ATG14, PIK3C3/VPS34 and PIK3R4/p150/VPS15; III)
the ATG12 conjugation system, involving ATG7, ATG10, ATG12,
ATG16L1 and ATG5; IV) the LC3 conjugation system, containing ATG4
proteases (ATG4A to ATG4D), ATG7, ATG3, WIPI2 and the members of
the LC3 protein family, and V) the ATG9 traﬃcking system, which in-
volves: ATG2A and ATG2B, WIPI4 and the transmembrane protein
ATG9A [4].
The process of autophagy can be divided at least in 6 discrete steps:
i) initiation, ii) nucleation of the phagophore, iii) expansion and closure
of the phagophore, iv) autophagosome fusion with a lysosome, v) de-
gradation of the autophagosomal cargo and vi) eﬄux of the resulting
metabolites from the lysosomes [5] (Fig. 1). The initiation step of au-
tophagosome biogenesis is marked by the association of certain ATG
proteins [1]. This event can be triggered by diﬀerent signalling
cascades, which modulate the activity of the ULK complex, the
PtdIns3K complex and/or the ATG9 traﬃcking system, and collectively
mediate phagophore nucleation. One example of a signalling pathway
regulating autophagy is the one centred on MTOR (mechanistic target
of rapamycin kinase) (Fig. 1). Under normal growing conditions, in the
presence on nutrients, MTOR phosphorylates ATG13 and ULK1 or
ULK2, inhibiting the kinase activity of the ULK complex. Upon starva-
tion, MTOR is inactivated and the ULK complex becomes depho-
sphorylated leading to its activation, which is required for the assembly
of the ATG machinery [1]. In addition to undergoing autopho-
sphorylation, the ULK complex also phosphorylates components of the
PtdIns3K complex and ATG9A, two modiﬁcations that appear to be part
of the initiation program of autophagosome formation [6,7]. The
PtdIns3K complex synthesizes phosphatidylinositol 3-phosphate
(PtdIns3P) on phagophore membranes, which acts as landmark to
Fig. 1. The mechanism of autophagy in mam-
malian cells. Upon autophagy initiation, a pha-
gophore nucleates and expand in close proximity
to the ER, in a specialized domain known as the
omegasome. Closure of the phagophore leads to
the formation of an autophagosome, which then
fuses with a lysosome to expose its cargo to the
hydrolytic enzymes present in the lumen of this
organelle. The ULK and PtdIns3K complexes, and
the ATG9 traﬃcking system are required for the
initiation, nucleation and expansion steps,
whereas the ATG12 and LC3 conjugation systems
are mainly involved in the closure of the pha-
gophore and autophagosome-lysosome fusion.
Table 1
Overview of the core ATG proteins and associated disorders.
Protein Functional group Disease








ATG9A ATG9 traﬃcking system CD [68]
ATG2A, ATG2B ATG9 traﬃcking system
WDR45/WIPI4 ATG9 traﬃcking system NBIA [74], Rett-like syndrome [81], EOEE [85,86], DEE [80]
ATG12 ATG12 conjugation system PD [92]
ATG10 ATG12 conjugation system VKHS [39], PDB [95]
ATG5 ATG12 conjugation system Asthma [32], BD [39], NMO [41], RA [42], SLE [47], systemic sclerosis [54], PD [88], ataxia [73], PDB
[95],
ATG16L1 ATG12 conjugation system CD [60], PDB [95], COPD [37]
WIPI2 ATG12 conjugation system
ATG7 ATG12 and LC3 conjugation systems CeD [69], PD [172]
LC3A to LC3C; GABARAP to L2 LC3 conjugation system PD [91]
ATG3 LC3 conjugation system
ATG4A to ATG4D LC3 conjugation system CD [67], KB [96], ataxia [71]
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recruit other ATG proteins to this precursor structure [8,9] (Fig. 1).
ZFYVE1/DFCP1 is one of the early-acting proteins and it may play an
important role in organizing the endoplasmic reticulum (ER) membrane
around the phagophore in such a way that it forms a cradle-like
structure, the omegasome (so named because of its Ω-structure) [1].
The ULK complex also appears to directly bind to ATG9A, possibly
through RB1CC1/FIP200 [10]. ATG9A is the only transmembrane
protein within the core ATG machinery, but it does not seem to in-
tegrate into the forming autophagosome, but rather has transient in-
teractions with it, which are required for the elongation of the phago-
phore [11] (Fig. 1). The forming autophagosome gathers its membranes
from several sites potentially including the ER, mitochondria, post-
Golgi compartments, recycling endosomes and the plasma membrane,
or contact sites between any of these [12–14].
The subsequent step, phagophore elongation, requires several fac-
tors including WIPI proteins. Although their exact function is unclear,
WIPI2 can recruit the ATG16L1 complex to the autophagosome [15].
ATG16L1, as part of the ATG12–ATG5-ATG16L1 complex, is re-
sponsible for recruiting members of the LC3 protein family onto the
phagophore membranes. LC3 proteins are ubiquitin-like proteins that
are post-translationally processed C-terminally by ATG4 proteases to
expose a glycine residue. ATG7 and ATG3, E1-like and E2-like enzymes,
respectively, conjugate LC3 proteins to the amino group of phosphati-
dylethanolamine (PE) [1]. The ATG12–ATG5-ATG16L1 complex is
formed through conjugation of ATG12 to ATG5 via the action of ATG7
and ATG10, another E2-like enzyme, and subsequent association with
ATG16L1. This complex interacts with and guides ATG3 to promote
LC3 linkage to PE in phagophore membranes [16]. There, LC3 proteins
are key for the closure and fusion of autophagosomes, but also play a
partial role in phagophore elongation [17]. In addition, the pool of
LC3–PE present on the concave surface of phagophores is crucial for the
recognition of autophagy receptors [18,19] (see below). Once the
phagophore seals, LC3–PE is likely removed from the outer membrane
of complete autophagosomes by the ATG4 proteases [20]. Complete
autophagosomes require the CCZ1-MON1 guanosine exchange factor
complex, its downstream eﬀector RAB GTPase RAB7, the homotypic
fusion and vacuole protein sorting tethering complex and SNAREs to
fuse with lysosomes and form autolysosomes [21,22]. The hydrolases
present in the lysosome then degrade the cargo carried by the autop-
hagosomes, and permeases present on the limiting membrane of this
organelle, transport these metabolites into the cytoplasm. Autolyso-
somes become lysosomes again through a process that has been termed
“autophagic lysosome reformation” [23]. During this process, tubules
emerge and extend from autolysosomes to become proto-lysosomes,
which eventually mature into lysosomes by acquiring new lysosomal
components.
1.2. Selective types of autophagy and autophagy receptors
Although autophagy can be a non-selective bulk process, in nu-
merous circumstances this pathway leads to the exclusive degradation
of targeted structures, which are speciﬁcally recognized and seques-
tered within autophagosomes through mechanisms that involve the so-
called autophagy receptors (Fig. 2 and Table 2) [24–26]. There are
several classes of selective types of autophagy that have been named
after the cargo targeted for degradation, e.g. aggrephagy for protein
aggregates, mitophagy for mitochondria, xenophagy for pathogens, ri-
bophagy for ribosomes, reticulophagy for ER, nucleophagy for the nu-
clear envelope, lipophagy for lipid droplets, lysophagy for lysosomes,
pexophagy for peroxisomes, etc. [24,26]. Selective types of autophagy
can be sub-divided into two categories, those that are ubiquitin-de-
pendent and entail autophagy receptors binding to this posttransla-
tional modiﬁcation, and those that are ubiquitin-independent and in-
volve the interaction of the autophagy receptors with other
determinants (Fig. 2) [26]. Of note, speciﬁc types of selective autop-
hagy such as mitophagy or xenophagy, have multiple autophagy
receptors to ensure the disposal of the targeted structure [26].
The ﬁrst mammalian autophagy receptor to have been characterized
is SQSTM1/p62 [25]. This protein was initially found to simultaneously
bind polyubiquitinated proteins present in protein aggregates and LC3
conjugated to phagophore membranes through the so-called LC3-in-
teracting region motif. SQSTM1 has now been linked to other types of
selective autophagy, such as mitophagy and xenophagy [24,26]. During
the past decade, additional autophagy receptors for one or more types
of selective autophagy have been identiﬁed, and include NBR1 (ag-
grephagy, pexophagy, lysophagy and midbody turnover), OPTN (opti-
neurin; aggrephagy, mitophagy and xenophagy), CALCOCO2/NDP52
(xenophagy and nucleic acid) and RETREG1/FAM134B (reticulophagy)
[24,26].
1.3. The physiological roles of autophagy and pathological consequences of
autophagic dysfunction
Because of its ability to rapidly turn over unwanted structures, au-
tophagy is integrally involved in a wide range of cellular and orga-
nismal functions that can be considered under the general concept of
homeostasis. These include adaptation to various types of stress, par-
ticipation in pathways of development and diﬀerentiation, contributing
to certain aspects of innate and adaptive immunity, acting in tumor
suppression, etc. Therefore, it is not surprising that mutations in genes
that aﬀect autophagic capacity can lead to severe illnesses. It must be
noted that the autophagy defects are indirect in some of these pathol-
ogies, such as in lysosomal storage disorders including Fabry and
Pompe diseases where lysosome malfunctioning causes impairment in
the fusion of autophagosomes with lysosomes and/or autophagosomal
cargo degradation [27,28]. Dysfunctional autophagy has also been
observed in large number of other diseases, including cancer, muscular
dystrophies and neurodegenerative disorders such as Alzheimer, Par-
kinson and Huntington diseases [29]. A still increasing number of re-
ports, however, has revealed that numerous diseases are caused or
appear to be caused by mutations in ATG genes and other genes in-
volved in autophagy. This review focuses on these pathologies with the
goal of giving a complete overview of congenital defects that could be
directly linked to impairment in autophagy. Although autophagy plays
an important role in numerous tumors, the exact contribution of this
pathway and associated changes is inﬂuenced by, and depends upon,
the speciﬁc tissue and what other mutations are present. Therefore, the
discussion about cancer and its associated autophagy-related mutations
deserve a separate review, because incorporating it would exceed the
length limits of the current review. Several comprehensive reviews on
cancer and autophagy have been published (e.g. [30,31].).
2. ATG and autophagy-associated genes as risk factors
2.1. Diseases caused by mutations in core ATG genes
2.1.1. Asthma
Asthma is a chronic inﬂammation of the airways that presents itself
most commonly as episodes of wheezing, shortness of breath, chest
tightness and coughing. Approximately 300 million people worldwide
suﬀer from this disease [32]. Because autophagy is implicated in im-
mune responses and inﬂammation, Martin and co-workers performed a
study in 2012 linking several single nucleotide polymorphisms (SNPs)
in ATG5 to diﬀerent asthma patient cohorts, the most notable of this
SNPs being ATG5 rs12201458, which localizes in the putative promoter
region of ATG5 [32]. Interestingly, acute asthma patients have in-
creased levels of ATG5 in nasal mucosal cells, and stable asthma pa-
tients have levels in between healthy controls and acute patients [32].
Asthma patients can continue to experience exacerbations despite
treatment, due to airway remodelling, or more speciﬁcally ﬁbrosis,
caused by collagen deposits in the airways. A more recent study as-
sociates ATG5 with these collagen deposits in airways, mainly those of
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COL5A1 [33]. In particular, the authors suggested that via angiotensin
II, autophagy could play a role in collagen deposition [33]. A study in
Korean patients and healthy controls, however, found no association
with asthma risk and ATG5 or ATG7 SNPs [34]. Nonetheless, the au-
thors discovered that sequence changes in ATG5 at -335G > A
(rs12201458) and 769T > C are associated with a higher sputum
neutrophil count, and two SNPs in ATG7, at 100A > G and
25108G > A, lead to higher IL8 levels in the serum [34]. As both
factors increase the severity of asthma, the main conclusion of this
investigation is that alterations in autophagy might play a role in the
disease course rather than its onset [34].
2.1.2. Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a disease where
there is an accelerated decline in lung function with periods of ex-
acerbations [35]. The incidence of COPD is growing and is currently the
fourth cause of death worldwide [36]. As autophagy has been asso-
ciated with COPD pathogenesis, a 2015 study explored whether speciﬁc
Cargo
Ubiquitin-independent
selective type of autophagy
Ubiquitin-dependent
selective type of autophagy





   Ubiquitin Activated ubiquitin- independent receptor
Fig. 2. Principles underlying selective types of autophagy.
Selective types of autophagy are subdivided into two categories,
ubiquitin dependent (left) and ubiquitin independent (right).
During the ubiquitin-dependent process, the cargo targeted to
degradation is post-translationally modiﬁed with single mole-
cules or chains of ubiquitin. Those tags are recognized by au-
tophagy receptors such as SQSTM1/p62 or NBR1, which in turn
interact with components of the ATG machinery, including
members of the LC3 protein family via a LC3-interacting (LIR)
motif. This allows the phagophore to speciﬁcally engulf the
cargo. During ubiquitin-independent types of autophagy, the
autophagy receptors are often proteins already present on the
structure. An example is RETREG1/FAM134B. The signal to
trigger selective autophagy activates this autophagy receptor by
inducing a change, which can be conformational and/or a post-
translational modiﬁcation such as a phosphorylation. In general,
this promotes the interaction of a LIR motif with one or more
members of the LC3 protein family, to coordinate the formation
of an autophagosome around the cargo.
Table 2
Autophagy receptors and related proteins, and associated disorders.
Protein Functional group Disease
SQSTM1/p62 Autophagy receptor ALS [100], FTD [113], FTD-ALS [119], AAS [120], DMRV [126], SIBM [128], PDB [122], childhood neurodegeneration [121]
OPTN Autophagy receptor ALS [109], FTD-ALS [119], PDB [124], NTG [141]
CALCOCO2/NDP52 Autophagy receptor CD [142]
RETREG1/FAM134B Autophagy receptor HSANIIB [138]
TOLLIP Autophagy receptor IPF [145], susceptibility to infectious diseases [149–152]
TBK1 Kinase ALS [173], NTG [141]
IRGM GTPase CD [64], NAFLD [144]
FA genes Mitophagy adaptors FA [148]
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genetic variants in ATG genes conferred susceptibility to smoking-re-
lated COPD [37]. The study found SNPs in ATG16L1 (rs 2,241,880,
T300A) but also in EGR1, a transcription factor that can regulate LC3
expression [37]. EGR1 involvement is not totally surprising as this
transcription factor is involved in the early response to oxidative stress,
which is a causative factor for COPD, and modulates the expression of
several genes involved in ﬁbrosis-like reactions, such as matrix me-
talloproteinases. The risk mutation in ATG16L1 is curious, as it is at the
same location as the one for Crohn disease (section 2.1.8), but the allele
that confers risk to COPD is the A, the unchanged one and coding for
T300, while that of Crohn disease is G (resulting in T300A) [37].
2.1.3. Behcet disease
Behçet disease (BD) is a rare and complex illness that is suspected to
be a systemic autoimmune disorder. It occurs mostly among people in
the Mediterranean and the Far East. Symptoms include apthous ulcers
(i.e., in the mouth or on the tongue), ulcers in the genital mucosa, eye
inﬂammation with possible vision loss, gastrointestinal inﬂammation,
vascular and articular inﬂammation and neurological inﬂammations
[38]. The risk factor most strongly associated with this disease is the
human leukocyte antigen (HLA)-B51 allele [38]. One study, however,
also linked ATG5 to BD in a Chinese patient cohort [39]. The TT SNP at
the ATG5 rs573775 is less common in BD patients and thus seems to
have a protective eﬀect. The TT genotype results in higher levels of
mRNA in response to lipopolysaccharide stimulation, and the authors
suggested that this could prevent a strong inﬂammatory reaction.
Curiously enough, BD patients have higher ATG5 mRNA levels com-
pared to healthy controls [39]. This study, however, did not provide
further experimental insights into the role ATG5 might play in BD in-
ﬂammatory responses, and research into this is needed.
2.1.4. Neuromyelitis optica
Neuromyelitis optica (NMO) is an autoimmune demyelinating dis-
ease of the optic nerves and spinal cord [40]. It is characterized by auto-
antibodies against the astrocyte water channel protein AQP4 (aqua-
porin 4) [40]. NMO leads to an inﬂammation of astrocytes, a sub-
sequent loss of neurons and astrocytes, and ultimately neuron demye-
lination [40]. A study in the southern Chinese Han population found
two ATG5 loci, rs548234 and rs6937876, associated with NMO. The C
allele frequency of rs548234 and the G allele of the rs6937876 SNPs are
more prevalent in NMO patients than in healthy controls [41]. Inter-
estingly, these SNPs are located in the ATG5-PRDM1 intergenic region,
which has also been linked to other autoimmune diseases, including
rheumatoid arthritis (RA) [41].
2.1.5. Rheumatoid arthritis
RA is chronic inﬂammatory disease that aﬀects the joints [42]. The
HLA antigen D related beta chain paralog (HLA-DRB1), in particular the
HLA-DRB1*0401 haplotype, is the highest risk factor for RA, but many
others have been identiﬁed and they are mostly involved in T-cell ac-
tivation [42,43]. One of these is the rs548234 SNPs at the intergenic
region between the PRDM1 and ATG5 genes, but this is only valid in
Caucasians and it cannot be found in the Chinese Han population
[42,44]. As a result, the genetic connection between RA and autophagy
is still not conclusive and it could be that some of the ATG genes have a
peculiar role in this disease.
2.1.6. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune dis-
ease where the body makes autoantibodies usually against double-
stranded DNA [45]. Patients suﬀer from inﬂammations throughout the
body, ranging from kidneys and lungs to the central nervous system,
heart and blood vessels. A common symptom is painful and swollen
joints, along with arthritis, and a hallmark manifestation is the so-called
butterﬂy rash that patients may display on their face. Painkillers and
corticosteroids are the only available treatments for patients suﬀering
from this disease as no cure for SLE exists [45]. Higher prevalence
within the same families or sets of twins indicates a strong genetic
component in the disease [46]. Over the past years many risk factors
associated with SLE have been found, including SNPs in ATG5
rs6937876 and rs548234, and a Chinese variant in MAP1LC3B
rs933717T [47,48].
ATG5 plays a role in the development of B cells, in particular in the
diﬀerentiation of plasma cells [49]. Because autoantibodies are a main
causative factor of SLE, and plasma cells play a central role in the
disease, it might be interesting to see whether ATG5 involvement in SLE
could be through its function in B-cell diﬀerentiation. As autophagy
degrades intracellular pathogens through a selective type of autophagy
called xenophagy, dysfunctional xenophagy could be another route
through which dysfunctional ATG5 poses a risk for the development of
SLE [47,50]. Infections, speciﬁcally with Epstein-Barr virus, have been
implicated in SLE [47,50]. The phenotype of ATG5 mutation carriers
appears to depend on IL10 levels, where the mutation confers a high or
low risk for SLE in high and low IL10 producers, respectively [51].
Another recent study showed that a defect in the clearance of dead cells
is also a deciding factor in SLE onset, and proposed that mutations in
ATG5 might be a risk factor because they could impair LC3-associated
phagocytosis (LAP) [52]. LAP is a form of phagocytosis, which plays a
role in the clearance of extracellular dying cells or pathogenic bacteria,
where a subset of the core ATG machinery leads to the conjugation of
LC3 to phagosomes [52]. Indeed, mice that are LAP deﬁcient develop a
SLE-like disease, characterized by increased cytokine and autoantibody
levels in the serum and decreased clearance of dead cells [52]. Exposing
these animals to dead cells exacerbate the disease phenotype [52]. In-
terestingly, the same does not happen with mice that have deletions in
genes encoding canonical ATG proteins that are not involved in LAP
[52].
A study trying to ﬁnd trans-expression quantitative trait loci of
ATG5 (elements that regulate expression of ATG5 in trans) found that
several of them were involved in ATG5 expression and increase the
ricks in developing lupus nephritis, a complication of SLE [53]. The role
of these genes in SLE or lupus nephritis remains to be ﬁrmly conﬁrmed
[53].
Altogether, these observations underline the point that there is de-
ﬁnitely a role of ATG5 and possibly other ATG proteins in the devel-
opment and severity of SLE. The etiological connection, however, re-
mains to be established, in particular whether autophagy, LAP or other
processes are directly linked with SLE.
2.1.7. Systemic sclerosis
Systemic sclerosis is another autoimmune disease characterized by
autoantibody generation. Characteristic symptoms are ﬁbrosis of the
skin and non-inﬂammatory vasculopathy [54]. Antibodies produced
include anti-centromere and anti-topoisomerase antibodies [54]. Pa-
tients' small blood vessels and other connective tissues are attacked and
damaged, and collagen is deposited in aﬀected areas [55]. The disease
can be fatal if heart, kidneys and/or lungs are targeted [55]. The main
genomic risk factor for this disease is associated with speciﬁc MHC class
II alleles, but many other risk loci have been identiﬁed. An attempt to
discover previously overlooked causal factors for susceptibility to sys-
temic sclerosis using microchip analysis identiﬁed ATG5 [54]. The
variants in ATG5 are at 6q21 but they are not exonic and consequently
they do not lead to mutations in the protein, indicating that all variants
may alter binding sites for DNA-binding proteins [54]. Thus, while the
association seems to be present, the exact role that ATG5 variants have
in the development of systemic sclerosis has to be investigated further.
2.1.8. Crohn disease
Crohn disease (CD) is an inﬂammatory bowel disease (IBD) that is
characterized by relapsing inﬂammation of the gastrointestinal tract
mucosa. In patients, this leads to abdominal pain, diarrhoea and fatigue
during relapses, and complications such as strictures, abscesses and
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ﬁstulas [56,57]. Remission is possible with medical therapies, but this is
often not indeﬁnite and many patients require surgical procedures [56].
CD is a multifactorial pathology and the exact causes remain unclear. A
factor involved in the disease appears to be an inappropriate immune
response to antigens in the intestinal lumen, speciﬁcally antigens be-
longing to the commensal ﬂora [57]. Approximately 100 loci have been
associated with IBD and the functions of the corresponding genes range
from bacterial recognition to lymphocyte activation and epithelial
protection [58]. Environmental factors are also involved, because dis-
ease often develops later in life, while predisposing genes are present
from birth [59].
In 2007, two studies comparing SNPs in CD patients with healthy
controls identiﬁed a risk factor at rs2241880 in the gene encoding
ATG16L1, i.e. corresponding to ATG16L1T300A [60,61]. It turns out that
ATG16L1 modulates SQSTM1/p62 ubiquitination via neddylation of
CUL3, which in turn supresses IL1B/IL-1β signalling [62]. Although
ATG16L1 rs2241880 does not inﬂuence the ATG16L1 protein levels or
autophagy activity, it decreases both ATG16L1 interaction with
TMEM59 through its WD40 domain, and the cellular response to Sta-
phylococcus aureus infection, and it increases IL1B signalling [62,63].
IRGM is another protein involved in autophagy, which has also been
associated with CD [64]. In this disease, IRGM has a protective role
possibly in the context of autophagy [64]. Variants at rs13361189 and
rs4958847 are important for susceptibility to CD [65]. A later genome-
wide association study (GWAS) also identiﬁed a signiﬁcantly higher
frequency of a SNP in ULK1 (rs12303764) in CD patients [66]. The
exact role of ULK1 in CD, however, has not been determined. Such a
connection would be interesting as it could indicate whether canonical
autophagy is important for CD development or whether the involve-
ment is limited to a subset of ATG proteins.
Formation of granuloma, possibly caused by the incomplete pro-
cessing of bacteria, can be observed in severe CD cases [67]. In a cohort
of surgically-treated patients, ATG4A rs5973822 and ATG4D
rs7248026, rs2304165 and rs10439163 variants are associated with
granuloma formation [67]. This could indicate that autophagy as a
whole also plays a role in CD. This notion is also partially supported by
a recent study that exploited circular chromosome conformation cap-
ture-sequencing to identify interactions between risk regulatory regions
and their putative target genes [68]. Many risk variants associated with
IBD were found not to be in genes but in DNA regulatory elements,
including the one of ATG9A [68].
Many autophagy proteins thus appear to play a role in the devel-
opment of CD. It remains to be ﬁrmly established whether mutations in
the ATG genes leads to CD by altering autophagy activity or other
pathways, such as the ones modulating IL1B signalling.
2.1.9. Celiac disease
Celiac disease (CeD) is a chronic autoimmune disease of the small
intestine, where ingesting dietary gluten leads to damage of this organ
[69]. A genome-wide and reﬁned mapping study of several auto-
immune diseases associated ULK3 rs1378938 with CeD [70]. The au-
thors conﬁrmed this connection by showing that biopsies from patients
carrying the risk T allele have increased expression of ATG proteins,
and increased expression of IL6 in response to lipopolysaccharides [70].
This observation indicated that one of the functions of autophagy—i.e.,
in immunity—could be involved in CeD [70]. Another study found that
autophagy could indeed play a role in CeD, and that ATG7, BECN1 and
their two regulating microRNAs, i.e. miR-17 and miR-30a, could serve
as biomarkers for CeD [69]. In particular, CeD onset can be detected
through the measurement of an autophagy decline in intestinal epi-
thelial cells by monitoring a decrease in ATG7 and BECN1 expression,
which is then followed by a reduction in MIR17 and MIR30 as part of a
putative compensatory mechanism [69]. Future studies will need to
identify what causes the diﬀerential expression of ATG proteins and
their microRNAs.
2.1.10. Vogt-Koyanagi-Harada syndrome
Vogt-Koyanagi-Harada syndrome (VKHS) is a systemic autoimmune
disease that principally causes an inﬂammation of the eye, but also
targets many other pigmented tissues in the body [39]. A SNPs analysis
aimed at exploring the possible involvement of ATG genes in 1061
VKHS patients from the Chinese Han population, determined that
having two A nucleotides at rs4703863 of ATG10 is associated with a
lower VKHS risk, whereas the C allele appears to confer a higher sus-
ceptibility to the disease [39]. This study, however, could not explain
the association between ATG10 and VKHS as there was no diﬀerence in
mRNA levels between these genotypes, nor there was a diﬀerence be-
tween patients [39]. Further research is needed to test whether ATG10
is indeed involved in VKHS syndrome, and, if so, how.
2.1.11. Ataxias
ATG4D is responsible for lipidating LC3-I and de-lipidating LC3-II.
In 2015, Kyöstilä and colleagues published a study linking a progressive
neurological disorder in Lagotto Romagnolo dogs to a missense muta-
tion in the animals' ATG4D gene [71]. The dogs suﬀer from progressive
cerebellar ataxia with, in some cases, involuntary eye movement and
behavioral changes. Histological analysis revealed vacuolization of
several tissues both inside and outside the brain, and axonal swellings.
Electron microscopy showed that the vacuoles have a single membrane
and are mostly empty in control samples, whereas they contain de-
generated mitochondria in axonal swellings, where autophagosomes
and cytoplasmic aggregates are also occasionally observed [71].
Linkage analysis and subsequent Sanger sequencing of the aﬀected
animals led to the association with the ATG4D gene (c.1288G > A; p.
Ala430Thr) [71], with 22 out of 25 dogs suﬀering from the disease
carrying this mutation. Because the residue is not in a known functional
part of the protein, but rather between the peptidase domain and the
BH3 motif near the carboxy terminus, it is unclear how this mutation
aﬀects the protein function [71]. Knocking down atg4a in zebraﬁsh,
however, results in neurological symptoms, providing further evidence
that the gene itself could cause the eﬀect. Aﬀected dogs have sig-
niﬁcantly higher LC3-II levels and a higher number of LC3-positive
spots under nutrient-rich conditions than healthy controls [72]. Using
baﬁlomycin A1 to inhibit lysosomal degradation results in an increase of
LC3-II vesicles in both healthy controls and aﬀected cells, showing that
only basal autophagy is aﬀected by the ATG4D mutation. One could
speculate that LC3-II is still generated, but the second function of
ATG4D, i.e. de-lipidating LC3-II, is hampered by the mutation and this
delays autophagosome fusion with lysosomes. Evidence to support this
hypothesis will require further research, but what is clear is that a ﬁnal
autophagosome maturation step appears to be delayed in this disease,
which probably causes the alteration seen in the nerve cells. Recently,
two young Turkish patients that had ataxia and developmental delay
since childhood were found to have a mutation in the ATG5 gene by
whole exome sequencing [73].
Overall, autophagy or ATG proteins appear to play major roles in
the development of ataxias.
2.1.12. β-propeller protein-associated neurodegeneration
ß-propeller protein associated neurodegeneration (BPAN) is a con-
dition belonging to a group of neurological disorders collectively
known as neurodegeneration with brain iron accumulation (NBIA)
[74]. All NBIAs show iron accumulation in the basal ganglia and this
iron accumulation can be diagnosed using magnetic resonance imaging
[75]. NBIA occurs in approximately 1 to 3 in 1,000,000 people [76].
There are seven other NBIAs, all with their own causative mutation, and
BPAN is one of them. BPAN is characterized by an early developmental
delay that remains static until further deterioration in adulthood,
leading to muscle stiﬀness and dementia. Because of these clinical
manifestations and the lack of iron accumulation, BPAN is a distinctive
form of NBIA [74] and it was originally called static encephalopathy of
childhood with neurodegeneration in adulthood (SENDA) [77]. Exome
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sequencing by Haack et al. and Saitsu et al. identiﬁed heterozygous
mutations in WDR45/WIPI4 at Xp11.23 as a causative factor of BPAN,
which is inherited dominantly [74,78]. The mutations were all de novo
mutations, and only two out of 20 subjects had the same mutation [74].
Sequencing of a heterogeneous NBIA cohort led to the identiﬁcation of
one patient with a missense mutation in WDR45, c.626CNA
p.Ala209Asp, and the clinical manifestation matched the pattern of
early developmental delay with further deterioration at a later age [79].
2.1.13. Developmental and epileptic encephalopathy
Patients with developmental and epileptic encephalopathy (DEE)
suﬀer from refractory seizures and epilepsy-like activity, which lead to
a developmental delay and even regression from an early age (as op-
posed to BPAN where the delay and degeneration onset is in adulthood)
[80]. A recent study aiming to establish whether DEE could also be
caused by mutations in WDR45, found 7 de novo mutations: 1 trunca-
tion, 5 indels leading to a frame-shift and one missense mutation
(Gly205Asp) [80]. Why these mutations result in DEE and not NBIA is
still unknown.
2.1.14. RETT-like syndrome
Rett syndrome is a neurodevelopmental disorder characterized by a
seemingly normal development during the ﬁrst years of life, which is
then followed by degeneration and loss of language and motor skills.
The disease mainly aﬀects girls [81]. Rett-like syndrome or alternative
Rett, is diagnosed when the patients meet a number, but not all, of the
criteria of Rett syndrome such as loss of hand skills, spoken language,
gait abnormality, breathing disturbances and growth retardation
[82,83]. WDR45 was linked to Rett-like syndrome through sequencing
studies in single patients. For instance, Hoﬀjan and colleagues de-
scribed an Argentinean patient with the splicing site mutation c.440-
2A > G in WDR45 [81]. In another case, however, the patient ap-
peared to have Rett-like syndrome, but was later diagnosed with BPAN
[84]. Like with DEE, it would be interesting to determine which WDR45
functions are disturbed to cause Rett-like syndrome and which others
lead to BPAN.
2.1.15. Early-onset epileptic encephalopathy
Whereas most changes in WDR45 sequence appear to aﬀect girls
and it is thought that the mutation of this gene might be lethal for
males, there are cases of males with a mutation in WDR45. In these
cases, the eﬀects manifest as early-onset epileptic encephalopathies
(EOEE), or least as epileptic seizures in combination with other neu-
rological issues [85,86]. It must be noted that EOEE patients do not
display an iron accumulation in the brain, distinguishing it from those
mutations inWDR45 causing BPAN and making it more similar to those
leading to Rett-like syndrome.
2.1.16. Parkinson disease
Parkinson disease (PD) is a neurodegenerative disorder, with tre-
mors as its hallmark symptom. PD is incurable and it aﬀects approxi-
mately 2% of the population over 50 years, resulting in approximately 6
million cases worldwide [87]. PD can be both familial and sporadic
[87]. The disease is characterized by the loss of dopaminergic neurons
in the substantia nigra, which causes progressive motor deﬁcits [87]. In
the aﬀected neurons, proteins aggregate in inclusions called Lewy
bodies, and they are mainly composed of SNCA/α-synuclein [87]. The
overexpression or aggregation of SNCA/α-synuclein causes dysfunction
of the mitochondrial respiratory chain leading to a decrease in ATP and
an increase in reactive oxygen species (ROS) [87]. Some risk factors of
PD, such as mutations in PRKN/PARKIN and PINK1, are associated with
proteins that are involved in mitophagy (paragraph 2.2.5). In agree-
ment with this notion, mutations in core ATG genes have also been
linked to PD. Speciﬁcally, several variations in the ATG12–ATG5 con-
jugation system and LC3B, but not ATG16L1, have been associated with
PD [88–92]. Mutations in the promoter of ATG5 (106,774,459T > A),
ATG7 (11313449G > A, 11313811T > C, 11313913G > A and
11314041G > A) and ATG12 (115842507G > T, 115842394C > T
and 115841817_18del) lead to higher expression levels of the corre-
sponding protein, something that correlates with observations in PD
patients' brain tissues [88,90,92]. Some variations in the LC3B pro-
moter region have also been discovered, but only one patient had a 21-
base pair insert that causes increased expression, while the other
changes that increase expression are only found in healthy controls or
in both PD patients and controls [91]. How all these variations aﬀect
the disease progression, and whether they are the cause or consequence
of the pathology, remains unclear. As the investigated patient group
and the number of patients with these variants aﬀecting expression
levels are low, it is unlikely that these variants are driving factors in PD
etiology. Nonetheless, further research could be relevant to establish
their role and that of autophagy in PD.
2.1.17. Paget disease of bone
In Paget disease of bone (PDB), osteoclasts induce osteolytic lesions,
which can lead to bone sclerosis and deformations over time [93]. PDB
is a chronic disease and the second most common bone disease
worldwide [94]. In this disease, osteoclasts appear to have cytoplasmic
inclusions and those could represent protein aggregates [95]. A study in
a cohort of Spanish patients found that polymorphisms in several ATG
genes is associated with PDB. These genetic changes included a C allele
in ATG16L1 rs2241880 and a G allele in ATG5 rs2245214, which in-
crease the risk of developing PDB, and a T allele in ATG10 rs1864183
that decreases the risk [95]. How these polymorphisms inﬂuence the
disease etiology remains to be established.
2.1.18. Kashin-Beck disease
Kashin-Beck disease (KB) is an osteoarthritis that is endemic to
China. KB causes degeneration of cartilage and cartilage matrix, and
chondrocyte necrosis and apoptosis in growth plate and articular car-
tilage [96]. Approximately 40% of the cases have been linked to genetic
factors [96]. Because diseased chondrocytes show dysfunctional au-
tophagy, a 2017 study explored whether autophagy, and more speci-
ﬁcally mutations inATG4C, could confer susceptibility to KB [96]. The
authors found signiﬁcant associations with ATG4C at rs11208030,
rs4409690, rs12097658 and rs6587988, and conﬁrmed that ATG4C
mRNA and protein levels are lower in KB chondrocytes [96]. This in-
vestigation, however, did not provide a functional explanation for the
association between ATG4C and KB, and solving this interrelationship
might oﬀer valuable insights into the speciﬁc function of ATG4C and
the role of autophagy in KB etiology.
2.2. Diseases caused by mutations in genes coding for autophagy receptors
and related proteins
2.2.1. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a
fatal neurodegenerative disorder that presents itself in adulthood. The
disease is characterized by cytotoxic protein aggregates in the large
motor neurons of the brain and the spinal cord [97,98]. The motor
neurons progressively lose their connection with their target muscles,
leading to their atrophy. The disease is fatal within several years, when
the respiratory muscles fail [99]. Approximately 3–5 people per
100,000 suﬀer from the disease in the United States and Europe, with
10% of these being familial ALS, where there is a usually a dominant
heritable genetic factor [99]. In 1993, mutations in SOD1 were found to
be a risk factor for ALS, and many others have subsequently been
identiﬁed and conﬁrmed in patients. Mice expressing mutant SOD1
variants such as SOD1G93A, display neurodegeneration and are used as
models for the disease. A few proteins connected to autophagy have
also been identiﬁed as risk factors for ALS, including SQSTM1/p62,
OPTN and TBK1 [100,101]. The SQSTM1/p62 autophagy receptor has
been found in ubiquitin-positive inclusions in ALS patients [102]. This
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protein also accumulates in the spinal cord of the SOD1G93A ALS mouse
model, together with ubiquitin and ALS variants of SOD1, but not wild-
type SOD1 [98]. Removing the ubiquitin-binding domain from
SQSTM1/p62 reduces these aggregates [98]. Because SQSTM1/p62 is
involved in both proteasome function and autophagy, it is not sur-
prising that mutations in this protein aggravate diseases characterized
by protein aggregates. Conversely, overexpression of SQSTM1/p62 re-
duces aggregates formed by TARDBP/TDP-43 (TAR DNA binding pro-
tein), another risk factor for ALS [103,104]. As an autophagy receptor,
SQSTM1/p62 is involved in selective types of autophagy, including
mitophagy, which appears to play a critical role in the pathogenesis of
ALS, as e.g. SOD1G93A mice show increased numbers of autophago-
somes, but not mitophagosomes, and an increased number of damaged
mitochondria [105]. Mitochondrial dysfunction plays a prominent role
in ALS, and SOD1G93A displaces HK1 (hexokinase 1) from its receptor in
the mitochondrial membrane, inhibiting its function in metabolism
[106,107]. The aﬀected motor neurons also show reduced levels of
SQSTM1/p62 and of other proteins involved in mitophagy, such as
BNIP3, PINK1, and PRKN [105]. Other ALS risk factors such as OPTN
and TBK1 are involved in this process as well; TBK1 regulates OPTN
and SQSTM1/p62 by phosphorylating their ubiquitin- and LC3-binding
sites during mitophagy [100]. Whereas it appears that SQSTM1/p62 is
mainly involved in ALS caused by mutated SOD1, OPTN function is
more prominent in sporadic ALS and SOD1-independent familial ALS
[108]. OPTN associates with damaged mitochondria extremities in-
dependently from SQSTM1/p62, triggering the recruitment of ZFYVE1/
DFCP1 and LC3 essential for subsequent mitophagy [109,110]. Deple-
tion of OPTN hampers mitophagy, and the ALS-associated OPTNE478G
mutant cannot rescue this phenotype [109,110]. Altogether, several
genes involved in providing speciﬁcity in selective types of autophagy
are mutated in ALS, and experimental evidence points to dysfunctional
mitophagy being part of the pathophysiology of this disorder. However,
it cannot be excluded that concomitant impairment of other autophagic
pathways, such as aggrephagy, contribute to ALS as they would pro-
mote the accumulation of intraneuronal aggregates when impaired.
Interestingly, one of the main risk factors for ALS, C9orf72, has recently
been found to bind the ULK1 complex and thus regulate autophagy
[111].
2.2.2. Frontotemporal dementia
Frontotemporal dementia (FTD), frontal lobe dementia, or Pick
disease, is a group of disorders that are caused by frontal or temporal
lobe atrophy, which hampers the cognitive abilities or the processing of
sensory inputs, respectively. Patients with FTD can present behavioral
changes, loss of language and dementia [112]. A study aimed to de-
termine whether common neurodegenerative diseases share mutations
in the promoter region of the SQSTM1/p62 gene, reached the conclu-
sion that many of them, including FTD, display an oxidative damage in
this chromosomal region that causes decreased transcription in the af-
fected tissues [113]. An earlier study also found SQSTM1/p62 accu-
mulating together with ubiquitin in cytoplasmic inclusions in neurons
and glia of FTD patients [114]. Consequently, a likely mechanism
whereby SQSTM1/p62 could be involved in preventing FTD develop-
ment is also through mitophagy. Interestingly, SQSTM1/p62 knock-
down decreases mitochondrial membrane potential to approximately
80% compared to controls by causing a drop in the levels of NADH,
which is required to generate an H+ gradient across the mitochondrial
inner membrane [115]. Low NAD(P)H and FAD levels are due to a non-
functional complex I in the mitochondrial respiratory chain, which has
the consequence of leading to higher ROS production in these SQSTM1/
p62-depleted cells, something that is also observed in other FTD neu-
rological disorders [115]. Mitochondrial dysfunction is likely an im-
portant factor in FTD pathogenesis, and SQSTM1/p62 could play a role
in the disease by being part of related and non-related autophagy
pathways. The ALS risk factor C9orf72, which was found to regulate
autophagy, is also a risk factor for ALS-FTD [111]. Moreover, CHMP2B,
a component of the ESCRT-III complex, which is important for autop-
hagosome maturation [116], has also been found to be mutated in FTD
[117].
2.2.3. FTD-ALS
ALS can also present itself with FTD symptoms, and this subtype of
the disease, which is observed in approximately 5% of ALS cases, is
known as ALS-FTD [118]. With increasing research and probably si-
milar mechanisms underlying ALS and FTD pathologies, ALS and FTD
are often seen as an ALS to FTD continuum [119]. OPTN and SQSTM1/
p62, as well as other factors that are involved in ALS, are also mutated
in ALS-FTD [118,119]. Whereas SQSTM1/p62 has not been shown to
have a direct role in mitochondrial respiration in either ALS or FTD,
mitochondrial dysfunction plays a role in both diseases, and a mito-
phagy defect would exacerbate both pathological phenotypes. With
SQSTM1/p62 and OPTN also found to be mutated in other diseases,
such as PDB, it would be interesting to determine how these pathways
are distinct and what intrinsic and extrinsic factors determine the de-
velopment of one particular disease rather than another.
2.2.4. Atypical apraxia of speech
Mutations in SQSTM1/p62 (p.Lys238del) that are seen in FTD can
also cause similar but distinctive phenotypes according to a study on
the possible relevance of mutations in SQSTM1/p62 in atypical apraxia
of speech (AAS) in one family [120]. The patients within this family
suﬀer from dysexecutive syndrome (i.e., lack of ability to perform ex-
ecutive functions such as planning and abstract though), visuo-con-
structional disabilities and apraxia of speech (i.e., an oral motor speech
disorder, rendering the translation of ideas to spoken words impossible)
[120]. Whereas the p.Lys238del mutation is seen in FTD and ALS
pathologies, the AAS patients have no motor neuron symptoms and do
not meet all FTD symptoms [120]. The authors of this study therefore
argued that SQSTM1/p62 mutations could result in heterogeneous
phenotypes and pointed out that patients with AAS or other behavioral
disorders associated with a visuo-constructive deﬁcit could also be
caused by SQSTM1/p62 dysfunction [120].
2.2.5. Childhood-onset neurodegeneration with ataxia, dystonia, and gaze
palsy
In addition to the study of AAS, another investigation found that
loss of SQSTM1/p62 causes a largely undeﬁned group of neurodegen-
erative disorders that share childhood-onset neurodegeneration with
ataxia, dystonia, and gaze palsy as symptoms [121]. Three diﬀerent bi-
allelic loss-of-function variants of SQSTM1/p62 (c.286C > T
(p.Arg96*), c.311_312del (p.Glu104Valfs*48) and c.2T > A were
found in four diﬀerent families [121]. This study thus also underlines
that pathologies related to SQSTM1/p62 mutations are heterogeneous
in their manifestation.
2.2.6. Paget disease of bone
As previously mentioned in section 2.1.17, PDB is characterized by
osteolytic lesions in osteoclasts, which can lead to sclerosis in the bone
and bone deformations over time [93]. Three mutations in the gene
encoding SQSTM1/p62 are found in familial PDB, and one of these also
in sporadic PDB. All these genetic changes aﬀect the ubiquitin-binding
domain of SQSTM1/p62 [122], but it remains unknown why they lead
to PDB. Further studies into PDB without SQSTM1/p62 mutations
identiﬁed rs1561570 in OPTN as a risk factor [123]. Another study
found that rs2234968, or rather two loci in linkage disequilibrium with
this SNP, cause alternative splicing of OPTN, resulting in a premature
stop codon and loss of protein function [124]. The same group also
found that OPTN levels in the rs3829923 variant can be upregulated by
the bone-related transcription factors TCF3/E47 and E2F1 [124]. This
observation could have explained the increased osteoblasts seen in PDB,
yet there was no in vivo eﬀect, which is probably why this variant was
not signiﬁcantly associated with PDB [124]. These data indicate that
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autophagy receptors play an important role in the development of PDB,
although the exact etiology remains to be established.
2.2.7. Distal myopathies with rimmed vacuoles
Distal myopathies are a heterogeneous group of muscle disorders
with approximately 20 diﬀerent forms, which are characterized by
weakness and atrophy of muscles in hands and/or feet. The diﬀerent
myopathy types can be traced to mutations in diﬀerent genes. Some are
autosomal recessive whereas others are inherited in a dominant fashion
[125]. Analyses of muscle biopsies of most distal myopathies show
disorganization of myoﬁbrils [126]. In some cases, the so-called rimmed
vacuoles, which appear to be accumulations of protein and membrane
debris with a possible autophagic origin, are detected in microﬁbers
[127]. Distal myopathies with rimmed vacuoles (DMRV) are also called
inclusion body myopathies and often occur in conjunction with PDB or
FTD [127]. One study of a family with autosomal dominant DMRV,
identiﬁed the c.1165+ 1 G > A splice donor variant in the SQSTM1/
p62 gene in the aﬀected individuals but also in one non-family related
patient [126]. Interestingly, DMRV patients also have SQSTM1/p62
inclusions [126]. Apart from the wild type protein, which is still pro-
duced in patients, the generated cryptic splicing site leads to two ad-
ditional versions of SQSTM1/p62, one deletion variant lacking the
PEST domain (i.e., SQSTM1ΔPEST2), and one truncated protein missing
the C-terminal UBA domain (i.e., SQSTM1ΔUBA-DK). These truncated
versions of SQSTM1/p62 result in a lower molecular weight protein
that is present in patient ﬁbroblasts and skeletal muscle cells [126].
SQSTM1ΔPEST2-expressing cells display large ubiquitin- and LC3-po-
sitive cytoplasmic and sarcoplasmic inclusions, which are very similar
to the inclusions present in DMRV patient cells. SQSTM1ΔUBA-DK, in
contrast, is homogenously distributed throughout the cell cytoplasm
and on striations in mouse skeletal muscle [126]. Moreover, it does not
colocalize with ubiquitin and LC3 [126]. DMRV can thus also be caused
by a defect in SQSTM1/p62. As rimmed vacuoles can be sporadically
seen in cells of people aﬀected by ALS, PDB and FTD, it would be in-
teresting to identify which other genetic and/or environmental factors
determine the eventual disease outcome.
2.2.8. Sporadic inclusion body myositis
Sporadic inclusion body myositis (SIBM) is the most common
myopathy in people over 45 years of age [128]. SIBM presents itself as a
characteristic pattern of progressive muscle weakness and atrophy in
proximal and distal muscles, especially the wrist and ﬁnger ﬂexors and
knee extensors [128]. While the exact nature of the disease, i.e. de-
generative or inﬂammatory, and its causes are unknown, there are some
key traits that serve as hallmarks, among which is the existence of
rimmed vacuoles, sarcoplasmic inclusions and deposits of degenerative
proteins [128]. One of these deposited proteins is SQSTM1/p62 [128].
Some missense mutations in SQSTM1/p62 (i.e. A117V, G194R, K238E
and P392L) have been found in SIBM patients. Because some of these
mutations are also associated with ALS, FTD or PDB, SIBM patients
have been screened to exclude these other pathologies. Patients car-
rying these mutations do not have increased expression of SQSTM1/
p62, but show increased expression of immune-related genes, such as
those corresponding to MHC class I and II [128]. The authors proposed
that the SQSTM1/p62 aggregates could be caused by increased protein
stability [128]. Although they do not provide insights into SIBM de-
velopment, SQSTM1/p62 variants could play a direct role other than
just accumulating in inclusions. Further research into their function and
prevalence is required to draw any conclusions. Interestingly, muta-
tions in FYCO1, a RAB7 eﬀector that directs autophagosome transport
on microtubules [129], also lead to SIBM [130].
2.2.9. Parkinson disease
PD is a neurodegenerative disorder described in section 2.1.15, that
is characterized by the loss of dopaminergic neurons in the substantia
nigra, causing progressive motor deﬁcits [87]. When overexpressed or
aggregated, SNCA/α-synuclein causes dysfunction of the mitochondrial
respiratory chain leading to a decrease in ATP and an increase in ROS in
the aﬀected neurons [87]. Not surprisingly, mitophagy appears to be an
important factor in PD. PINK1 and PRKN are proteins that are com-
monly found mutated in autosomal recessive PD cases. The PINK1 ki-
nase is stabilized upon mitochondrial damage, promoting its phos-
phorylation of PRKN, necessary for the recruitment and activation of
this E3 ubiquitin ligase onto the mitochondrial outer membrane [87].
PRKN has a number of downstream targets that are recognized by au-
tophagy receptors and enable the formation of LC3-positive phago-
phores adjacent to the damaged mitochondria to promote mitophagy
[87]. There is redundancy within the autophagy receptors that are re-
cruited, i.e. SQSTM1/p62, OPTN, NBR1, CALCOCO2/NDP52 and
TAX1BP1, and this could explain why mutations in these proteins are
not found to cause PD, although SQSTM1/p62 and NBR1 do localize to
PD inclusions [131,132]. A factor regulating these autophagy receptors
is their phosphorylation by TBK1 [100]. Yet, intriguingly enough,
whereas PINK1 is required for TBK1 function, and thus OPTN function,
TBK1 and OPTN mutations are only associated with ALS and not with
PD, while PINK1 is associated only with PD [100]. PRKN and PINK1
also interact with the kinesin adaptor protein RHOT1/Miro1 to trigger
its proteasomal turnover, which leads to the dissociation of damaged
mitochondria from the cytoskeleton promoting their engulfment by
phagophores [133]. A third protein associated with PD is LRRK2, which
under normal circumstances forms a complex with RHOT1/Miro1 es-
sential for its proteasomal degradation, but not when carrying a PD-
associated mutation [134]. LRRK2 downregulation increases autop-
hagy, and causes accumulation of autophagic structures [135]. There-
fore, LRRK2 could also genetically link PD development with impair-
ment in mitophagy. Yet, while LRRK2 is found on mitochondria, and
the G2019S variant alters mitochondrial morphology, ROS levels and
mitochondrial membrane potential, there is no direct link between this
protein and mitophagy [135]. While the roles of PINK1, PRKN and
LRRK2 in preventing PD can be linked to mitophagy, it remains unclear
why other proteins involved in this pathway are not found mutated in
PD patients and why related mutations lead to ALS rather than PD.
2.2.10. Hereditary sensory and autonomic neuropathy II B
Hereditary neuropathies are a heterogeneous group of diseases that
are classiﬁed by their alterations of motor, sensory or autonomous
neurons [136]. Hereditary sensory and autonomic neuropathy II
(HSANIIB) is a rare sensory and autonomic neuropathy leading to re-
duced sensation to touch, cold and pain [137]. This often results in
infections, osteomyelitis and mutilations, with the possible requirement
of limb amputation in patients, similar to leprosy [138]. In 2009, mu-
tations in RETREG1/FAM134B were identiﬁed as a causative factor for
one of the subtypes of HSANIIB [138,139]. Initially, it was thought that
RETREG1 was a Golgi protein, as its depletion results in a dis-
organization of this organelle [139]. Khaminets, et al., however,
showed that RETREG1 serves as an autophagy receptor for re-
ticulophagy and the mutations found in HSANIIB patients result in a
protein unable to carry out its receptor function [140]. This defect has
the ultimate consequence of causing an expansion of the ER due to an
inhibition in its turnover, which in turn sensitizes the cells to apoptosis,
leading to the sensory neuron loss seen in HSANIIB [140].
2.2.11. Normal tension glaucoma
Glaucomas are a set of neurodegenerative disease aﬀecting retinal
ganglion cells, which leads to degeneration of the optic nerve ﬁbers and
ultimately to blindness [141]. Glaucomas are subdivided into diﬀerent
types, and one of them, the normal tension glaucoma (NTG), is asso-
ciated with mutations in OPTN [141]. The OPTNM98K variant, in par-
ticular, is a risk factor for NTG [141]. This variant provokes an increase
in TFRC (transferrin receptor) uptake by phagophores, leading to an
imbalance in the cells' iron metabolism and consequent cell death
[141]. TBK1 is required to functionally link OPTN to LC3, and TBK1
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mutations can similarly cause NTG [141]. If modulation of autophagy
ameliorates NTG and possibly other neurodegenerative diseases, this is
certainly worth deeper investigation.
2.2.12. CROHN'S disease
As explained in section 2.1.7, CD is an IBD that is characterized by
relapsing inﬂammation of the gastrointestinal tract mucosa. A 2013
whole exome sequencing study with single nucleotide variant ﬁltering
found that SNP rs2303015 (Val248Ala) of CALCOCO2/NDP52 also
confers susceptibility to CD [142]. CALCOCO2/NDP52 is a selective
autophagy receptor for xenophagy [142], and it also plays an im-
munosuppressive role in NFKB/NF-κB signalling through toll-like re-
ceptors (TLRs), including TLR3. The Val248Ala mutant, however, is
unable to negatively regulate NFKB signalling. As CALCOCO2/NDP52
but not the Val248Ala variant is degraded by autophagy and the pro-
teasome after being ubiquitinated when TLR3 is activated, the authors
propose that one or more post-translational modiﬁcations of CAL-
COCO2/NDP52 could be aﬀected by the mutation, making the protein
more stable and thus increasing NFKB signalling [142]. Nonetheless,
this rare variant in CALCOCO2/NDP52 could strengthen the notion of a
role of autophagy in CD.
2.2.13. Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is characterized by the
progressive accumulation of fat in the liver. Because autophagy can
regulate fat metabolism through lipophagy, it seemed reasonable to test
whether mutations in ATG genes are associated with NAFLD [143].
Thus, IRGM has been linked with NAFLD susceptibility [144]. In par-
ticular, ﬁve SNPs in the IRGM gene were found to be risk factors for
NAFLD, and especially the rs10065172 TT genotype increases the odds
of NAFLD by 2.059 [144]. The siRNA-based knockdown of IRGM results
in lower autophagic ﬂux and doubles the number of lipid droplets in
HepG2 and PLC/PRF/5 cells, a phenotype that can be rescued by in-
ducing autophagy with rapamycin, and phenocopied by inhibiting this
pathway with wortmannin [144]. Accordingly, cells overexpressing a
GFP-tagged version of IRGM appear to show a decrease in the number
and size of lipid droplets. The authors thus proposed that IRGM is re-
quired for lipophagy in hepatocytes and that the rs10065172 TT gen-
otype puts people at risk for NAFLD [144].
2.2.14. Idiopathic pulmonary ﬁbrosis
Idiopathic pulmonary ﬁbrosis (IPF) is a rare but severe disease that
is often fatal, where excessive ﬁbrous tissue is formed in the lungs
[145]. The only treatment option is a lung transplant [145]. A GWAS
identiﬁed three SNPs in TOLLIP, i.e., rs111521887, rs5743890 and
rs5743894, which all lead to a reduced expression of TOLLIP, ranging
from 20 to 50% of the normal levels [145]. Curiously, the G allele at
rs5743890 in TOLLIP is more often seen in healthy people than in pa-
tients, suggesting that it could confer a protective eﬀect but it increases
the mortality risk when the disease develops [145]. In addition to being
involved in selective types of autophagy [146], TOLLIP participate in
TLR signalling, and in intracellular traﬃcking and the degradation of
TGFB (transforming growth factor beta) type 1 receptors [145]. A focus
for further research into IPF should be on the eﬀect of these SNPs at the
cellular level, and how this could explain the disease development and
severity.
2.2.15. FANCONI anemia
Fanconi anemia (FA) is a rare and complex disorder caused by
mutations in one or more of the 16 proteins that function together in
repairing DNA damage caused by crosslinking [147]. Patients with
mutations in any of the FA genes are often diagnosed when they start to
suﬀer from bone marrow failure in adulthood. Other symptoms are in
line with outcomes expected with a dysfunction in a DNA damage re-
pair pathway; that is, acute myeloid leukemia, reduction in mature
blood cells, hearing failure, endocrine and gastrointestinal
abnormalities, congenital limb deformities, skin hyper-pigmentation,
low bone density and high risks of developing solid tumors [147]. Two
FA genes are infamous for their involvement in familial breast cancer
and ovarian cancer development: BRCA1/FANCS and BRCA2/FANCD1
[148]. Some of the proteins in the FA pathway have functions other
than DNA damage repair. A recent study found that FANCC is involved
in virophagy and mitophagy, and that FANCA, FANCF, FANCL,
FANCD2, BRCA1 and BRCA2 are all also required for mitophagy [148].
Moreover FANCC interacts with PRKN [148]. FANCC mutants are
known for a hypersensitive inﬂammatory cytokine response, which is
independent from the role of this protein in DNA-damage repair [148].
Interestingly, a mutation in FANCC that produces a shorter protein, i.e.
c.67delG, results in a milder disease phenotype [148]. Cells expressing
c.67delG protein cannot repair DNA damage but have normal clearance
of dysfunctional mitochondria through mitophagy and are also not
sensitive to inﬂammatory cytokine cell death [148]. The role in hy-
persensitivity thus appears to segregate with its role in mitophagy. This
observation suggests that impairment of one or more functions con-
nected with autophagy could be part of the pathophysiology of FA, in
particular when FANCC is mutated [148].
2.2.16. Infectious diseases
Whereas infectious diseases are not directly caused by gene muta-
tions, there are mutations that can confer susceptibility to infection.
Mutations that aﬀect the autophagy receptor TOLLIP are associated
with susceptibility to several infectious diseases: leprosy, leishmaniasis,
tuberculosis and sepsis [149–152]. TOLLIP also negatively regulates
TLR signalling via IL6 (interleukin 6), TNF/TNF-α and IL10 [150]. For
leprosy, the rs3793964 TT variant confers susceptibility to Myco-
bacterium leprae and is linked to increased expression of TOLLIP and
IL1R1/IL-1Ra in the skin [149]. The rs5743899 and rs3750920 SNPs, in
contrast, are associated with leishmaniasis and tuberculosis [150,151],
whereas the rs5743867 SNP confers susceptibility to sepsis by in-
creasing TOLLIP mRNA and decreasing IL6 and TNF levels [152]. Of
note, UKL1 variants causing susceptibility to Mycobacterium tuberculosis
have been identiﬁed [153]. Whereas TOLLIP can act as an autophagy
receptor, whether the major role of TOLLIP in preventing infectious
diseases is linked to this function or to its modulation of TLRs, or both,
remains to be elucidated.
3. Conclusions
In this review, we have tried to provide a complete list of those
congenital pathologies that are caused by or could be caused by mu-
tations in genes that encode proteins that are part of the core autophagy
machinery, that function as autophagy receptors or that are otherwise
related to this process (Tables 1 and 2). It must be noted that this list is
not exhaustive due to space limitations; we did not cover, for example,
those diseases that are due to alterations in genes known to be involved
in autophagy but not part of the core ATG machinery. One such ex-
ample is the Charcot Marie Tooth 2B (CMT2B) disease, which is an
inherited peripheral neuropathy characterized by the loss of peripheral
sensory and motor functions rather than sensory and autonomous
functions, and is caused by genetic alterations in RAB7 that lead to high
levels of the active form of this RAB GTPase [136,154]. CMT2B
symptoms can be explained by major lysosomal and autophagic activ-
ities leading to a premature breakdown of the nerve growth factor
(NGF) receptor NTRK1/tropomyosin receptor kinase A, resulting in
impaired NGF binding and signalling [155].
Another example is Vici syndrome, a recessively inherited multi-
system disorder that is invariably fatal [156]. Children with this disease
have a poorly developed corpus callosum (callosal angenesis), catar-
acts, cardiomyopathy, hypopigmentation, progressive microcephaly,
failure to thrive, a global development delay and immunodeﬁciency
[156]. EPG5 is the causative locus for Vici syndrome [157] and the
encoded protein also appears to be a RAB7 eﬀector involved in
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autophagosome maturation [158], but that is also be responsible for
transporting the TLR9 ligand CpG to the late endosomal-lysosomal
compartments [156].
Finally, hereditary spastic parapesis or paraplegia (HSP) is char-
acterized by axonal degradation of the corticospinal motor- and sensory
neurons, which leads to partial (i.e., parapesis) or complete (i.e.,
paraplegia) loss of limb motor control causing spasticity, progressive
weakness and hyperreﬂexia of the lower limbs [159]. Three autosomal
recessive variants of HSP are associated with loci indirectly involved in
autophagy: SPG11/SPATACSIN, ZFYVE26/SPG15/SPASTIZIN and
CYP2U1/SPG49 [160,161]. ZFYVE26 interacts with the PtdIns3K
complex, which is responsible for autophagosome maturation as it is
involved in endosomal traﬃcking. Patient gene variants lead to trun-
cated proteins or to an inability of ZFYVE26 to bind this PtdIns3K
complex. ZFYVE26 interacts with SPG11, and when one of these two
proteins is depleted, aﬀected cells show increased numbers of enlarged
autophagosomes and decreased numbers of lysosomes [160]. CYP2U1
is a more recently discovered variant of HSP, caused by mutations in
TECPR2 (tectonin beta-propeller repeat containing 2) [161]. TECPR2
regulates COPII-dependent ER export, and as ER-exit sites are important
for early autophagosome formation, it may be that mutations in
TECPR2 aﬀect this ER subdomain and indirectly impair autophagy
progression [162].
It is interesting to note that most diseases due to a genetic alteration
of autophagy can be classiﬁed as either neurological disorders or in-
ﬂammatory pathologies (Tables 3 and 4). This is not an entirely sur-
prising observation. A process such as autophagy that is vital for cell
homeostasis is naturally more important in post-mitotic neurons than in
cell types capable of regeneration. Several autophagy receptors, which
direct the selective breakdown of compromised proteins or organelles,
lead to neurodegeneration when mutated. For example, mutated OPTN
is associated with ALS, FTD-ALS and NTG, whereas mutated SQSTM1/
p62 is associated with ALS, PD, FTD, FTD-ALS and AAS (Table 2). Not
surprisingly, many of these diseases are characterized by the accumu-
lation of cytoplasmic aggregates and dysfunctional organelles, in-
cluding mitochondria. OPTN and SQSTM1/p62 are risk factors of an-
other illness, PDB, which is not neurological but presents cytoplasmic
inclusions. Interestingly, the aﬀected cells are osteoblasts that, similar
to neurons, do not divide and therefore could rely greatly on autophagy
to eliminate damage.
The link between inﬂammatory diseases and autophagy dysfunction
is also not surprising. In addition to being relevant for the turnover of
intracellular pathogens through xenophagy, autophagy regulates nu-
merous aspects of immunity, including control of inﬂammation through
various mechanisms, secretion of immunomediators and adaptive im-
munity, development of diﬀerent subtypes of immune cells, im-
munotolerance, etc. [163]. Consequently, it is easy to imagine that
autophagy alterations could have a negative multisystemic eﬀect on the
immune system, thus promoting predominantly the development of
inﬂammatory diseases. In this regard, it is interesting to highlight that
null and missense mutations are only found in autophagy receptors and
related proteins, but not in the core ATG machinery, where most of the
genetic changes do not have a major impact on the function of the
protein. Because of the multitude of physiological roles of autophagy, it
is expected that the absence of a core ATG gene is prenatally lethal. In
contrast, loss of an autophagy receptor would only aﬀect a subset of
selective types of autophagy, and as a result the onset of the disease can
also be postnatal. This consideration is in keeping with the ﬁnding that
knockout mice lacking core Atg genes die during embryonic develop-
ment or shortly after birth, whereas mice lacking SQSTM1/p62 or
NBR1 live longer [164–166]. An exception appears to be WDR45/
WIPI4, but in most of the cases the manifestations of the diseases as-
sociated with this protein are sporadic and, when genetically inherited,
the loss of function is probably compensated by WDR45B/WIPI3 as
shown in cell-line studies [167].
Although it was thought for a long time that ATG proteins solely
regulate autophagy, we now know that they are also involved in-
dividually or in groups in other pathways through so-called non-cano-
nical functions [1,4]. As a result, some of the described pathologies
could be due to the alteration of one of the non-canonical functions or a
combinatorial eﬀect together with an impairment of autophagy. For
example, the ATG5 variants leading to SLE also alter LAP, a pathway
that is clearly linked to the disease progression. Thus, while learning
more about the etiology of several diseases and their genetic predis-
positions, we might acquire insights not only into autophagy and its
roles, but also into non-canonical functions of ATG proteins. Con-
versely, increasing our knowledge about the mechanisms and physio-
logical roles of autophagy, but also about the non-canonical functions
of ATG proteins, could help in deciphering the pathophysiology of some
diseases.
We are just at the beginning of a long journey, but the combination
of genetic and functional information could pave the way to the de-
velopment of optimal therapies to cure, or at least delay, the onset of
speciﬁc illnesses. Most of the current autophagy-based therapies rely on
drugs such as rapamycin or chloroquine, which are far from being
speciﬁc as they alter numerous cellular pathways other than autophagy
[168,169]. Although there is a global eﬀort in developing more speciﬁc
compounds that exclusively target ATG proteins, their involvement in
other processes and the multiple roles of autophagy, makes this task
very diﬃcult. Understanding the exact molecular principles underlying
both autophagy and the associated disease could be of great help to
achieve this task, as well as exploring combinatorial approaches were
autophagy is modulated by physiological means, for example with a
protein-poor diet and/or exercise [170,171].
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